

1 **HIV-1 drug resistance in people on dolutegravir-based ART:**
2 **Collaborative analysis of cohort studies**

3

4 Tom Loosli^{1,2}, Stefanie Hossmann³, Suzanne M. Ingle⁴, Hajra Okhai⁵, Katharina Kusejko^{1,2},
5 Johannes Mouton⁶, Pantxika Bellecave⁷, Ard van Sighem⁸, Melanie Stecher^{9,10}, Antonella d'Arminio
6 Monforte¹¹, M. John Gill^{12,13}, Caroline A. Sabin⁵, Gary Maartens⁶, Huldrych F. Günthard^{1,2}, Jonathan A.
7 C. Sterne⁴, Richard Lessells^{15,16,*}, Matthias Egger^{3,4,16,*}, Roger Kouyos^{1,2,*}

8 * Authors contributed equally

- 9 1. Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich,
10 Zurich, Switzerland
11 2. Institute of Medical Virology, University of Zurich, Zurich, Switzerland
12 3. Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland
13 4. Population Health Sciences, Bristol Medical School, University of Bristol, UK
14 5. Institute for Global Health, University College London, UK
15 6. Department of Medicine, University of Cape Town, Cape Town, South Africa
16 7. Virology laboratory, University Hospital Bordeaux, Bordeaux, France
17 8. Stichting hiv monitoring, Amsterdam, the Netherlands
18 9. German Center for Infection Research (DZIF), Partner-Site Cologne-Bonn, Cologne, Germany
19 10. University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of
20 Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf
21 11. Italian Cohort Naive Antiretrovirals, (ICONA) L'Azienda Socio Sanitaria Territoriale (ASST)
22 Santi Paolo e Carlo, Milano, Italy
23 12. Southern Alberta Clinic, Calgary, AB, Canada
24 13. Department of Medicine, University of Calgary, Calgary, AB, Canada
25 14. KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), University of KwaZulu-
26 Natal, Durban, South Africa
27 15. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa
28 16. Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences,
29 University of Cape Town, Cape Town, South Africa

30

31 Correspondence to: Prof Matthias Egger MD; matthias.egger@ispm.unibe.ch

32

33 **Word counts:** Abstract 293 words, research in context 432 words, main text 3281 words, 2 tables, 4
34 figures, 39 references, online appendix with 12 pages.

35 Summary

36

37 **Background:** The widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG)
38 in first- and second-line antiretroviral therapy (ART) may facilitate emerging resistance. We
39 combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and
40 identify risk factors for DTG resistance.

41 **Methods:** Eight cohorts from Canada, Europe, and South Africa contributed data on individuals with
42 genotypic resistance testing on DTG-based ART. Resistance levels were categorised using the
43 Stanford algorithm. We identified risk factors for resistance using mixed-effects ordinal logistic
44 regression models.

45 **Results:** We included 750 people with genotypic resistance testing on DTG-based ART between 2013
46 and 2022. Most had HIV subtype B (N=444, 59.2%) and were treatment-experienced; 134 (17.9%)
47 were on DTG dual and 19 (2.5%) on DTG monotherapy. INSTI DRMs were detected in 100 (13.3%)
48 individuals; 21 (2.8%) had more than one mutation. Most (N=713, 95.1%) were susceptible to DTG, 8
49 (1.1%) had potential-low, 5 (0.7%) low, 18 (2.4%) intermediate and 6 (0.8%) high-level DTG
50 resistance. The risk of DTG resistance was higher on DTG monotherapy (adjusted odds ratio (aOR)
51 37.25, 95% CI 11.17 to 124.2) and DTG lamivudine dual therapy (aOR 6.59, 95% CI 1.70 to 25.55)
52 compared to combination ART, and higher in the presence of potential-low/low (aOR 4.62, 95% CI
53 1.24 to 17.2) or intermediate/high-level (aOR 7.01, 95% CI 2.52 to 19.48) nucleoside reverse
54 transcriptase inhibitors (NRTI) resistance. Viral load on DTG showed a trend towards increased DTG
55 resistance (aOR 1.42, 95% CI 0.92 to 2.19 per standard deviation of \log_{10} area under the viral load
56 curve).

57 **Interpretation:** Among people experiencing virological failure on DTG-based ART, INSTI DRMs were
58 uncommon, and DTG resistance was rare. DTG monotherapy and NRTI resistance substantially
59 increased the risk for DTG resistance, which is of concern, notably in resource-limited settings.

60 **Funding:** US National Institutes of Health, Swiss National Science Foundation.

61 **Research in context**

62 **Evidence before this study**

63 We searched SCOPUS on 20 March 2023 for all publications from inception using the terms
64 “dolutegravir” or “DTG”, “resistant” or “resistance”, and “HIV”. The available evidence on resistance
65 evolution in people living with HIV (PLHIV) with virological failure on DTG-based ART is limited. Most
66 studies assessed the efficacy of DTG-based regimens in clinical studies and reported drug resistance
67 in individuals experiencing virological failure as a secondary objective or reported single or multiple
68 cases of patients developing resistance on DTG-based ART. Clinical trials such as the NADIA trial
69 showed a high degree of viral suppression even in people with NRTI resistance. Consequently,
70 previous analyses included only a small number of people experiencing failure on DTG; the SINGLE
71 trial with 39 people with virologic failure on DTG was the largest. The highest number of individuals
72 with DTG resistance was nine study participants in the NADIA trial. There is evidence that DTG
73 resistance in PLHIV on a DTG monotherapy may be more likely. Other studies suggest that HIV
74 subtype and mutations acquired during a first-generation INSTI-based regimen might affect the risk
75 of DTG resistance.

76 **Added value of this study**

77 To our knowledge, this is the first study systematically investigating resistance in PLHIV experiencing
78 virologic failure on DTG-based ART using a multi-cohort collaboration design reflecting real-world
79 routine care. We collected genotypic resistance tests and clinical data from eight observational HIV
80 cohorts. This resulted in a large dataset of PLHIV experiencing virologic failure on a DTG regimen
81 (over 700 individuals). It allowed a robust assessment of drug resistance mutations and risk factors
82 for DTG resistance. Cross-resistance of first-generation INSTIs does not appear to explain the
83 mutation patterns in HIV-infected individuals who experience virological failure on DTG-based ART
84 regimens. PLHIV who received DTG monotherapy or DTG lamivudine dual therapy and those infected
85 with non-B subtypes were more likely to develop resistance. Resistance to NRTIs was a major risk
86 factor for DTG resistance, indicating that PLHIV receiving functional monotherapy are more likely to
87 develop DTG resistance.

88 **Implications of all the available evidence**

89 HIV drug resistance is a significant threat to the sustainability of current and future antiretroviral
90 therapy for combating the ongoing HIV pandemic. Our collaborative analysis shows that cases of
91 DTG resistance are so far rare but not negligible. Given the global DTG roll-out, this might lead to
92 increased frequencies and transmission of DTG resistance, particularly in PLHIV with resistance to

93 NRTIs. While the evidence regarding subtype differences is tentative, it indicates that non-B
94 subtypes, which are most relevant for the global roll-out of DTG, might be associated with an
95 increased risk of resistance.

96 Introduction

97 The integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) was approved in 2013 in the United
98 States and shortly afterwards in the European Union to treat HIV infection. In 2019, the World
99 Health Organization (WHO) recommended DTG as the preferred drug for first-line and second-line
100 antiretroviral therapy (ART) in all populations, including pregnant women and those of childbearing
101 age. Since then, DTG-based ART was rolled out globally,¹ with about 100 countries including DTG in
102 their treatment guidelines by mid 2020.²

103 DTG has a high genetic barrier to resistance,^{3,4} and relatively few people living with HIV (PLHIV) are
104 so far known to have developed resistance.⁵⁻⁷ The mutations leading to DTG resistance may differ
105 between HIV subtypes. In INSTI-naïve PLHIV, DTG resistance is mainly associated with the R263K
106 mutation,^{8,9} which was observed in three cases of DTG resistance in the NADIA trial.¹⁰ The N155H
107 mutation was present in two individuals with subtype A and C in the SAILING trial,¹¹ while the G118R
108 mutation appears to be facilitated by a natural polymorphism in subtype C.¹² In a recent study in
109 Ethiopia, the Q148H/K/R mutation was found to be less prevalent in subtype C.¹³ Pre-existing
110 mutations, such as those acquired during a first-generation INSTI regimen, may directly confer
111 resistance to DTG or affect the accumulation of additional mutations.^{14,15}

112 The risk factors and the mutational patterns that confer resistance to DTG in vivo are less well
113 established than for older antiretroviral drugs.¹⁶ The widespread use of DTG in resource-limited
114 settings, where ART regimens are highly standardised, drugs are recycled, access to adherence
115 support, viral load and resistance testing is limited, may facilitate the emergence of resistance. We
116 combined data from European, North American, and South African cohorts to identify risk factors for
117 DTG resistance and to examine the patterns of resistance mutations across different HIV subtypes.

118 Methods

119 Data sources

120 We pooled data from eight HIV cohorts, including six European, one Canadian, and one South
121 African cohort: the AIDS Therapy Evaluation in the Netherlands cohort (ATHENA),¹⁷ the Agence
122 Nationale de la Recherche sur le SIDA et les hépatites virales (ANRS CO3), Aquitaine Cohort,¹⁸
123 the Italian Cohort of Antiretroviral-Naïve Patients (ICONA),¹⁹ the Köln/Bonn Cohort (CBC),
124 Germany,²⁰ the UK Collaborative HIV Cohort (UK CHIC) Study (and linked UK HIV Drug Resistance
125 Database (UKHDRD)),²¹ the Swiss HIV Cohort Study (SHCS),²² the South Alberta Clinic Cohort
126 (SAC), Canada,²³ and the South African Aid for AIDS (AfA) cohort.²⁴ The European and North-
127 American cohorts (apart from UK CHIC) participate in the ART Cohort Collaboration (ART-CC)²⁵ and

128 AfA in the International epidemiology Databases to Evaluate AIDS (IeDEA).²⁶ The clinical data were
129 provided by the data centres of the two cohort collaborations, and the genotypic data by the
130 cohorts.

131 **Inclusion criteria**

132 Participants who underwent genotypic resistance testing from plasma HIV-1 RNA covering the
133 integrase gene between two weeks after starting and up to two months after stopping any DTG-
134 based regimen were eligible. In the case of multiple genotypic resistance tests, the latest was
135 considered. Participants with unknown dates of initiation of DTG-based ART were excluded. The
136 analysis of risk factors for DTG resistance was restricted to individuals with at least one year of
137 follow-up.

138 **HIV drug resistance**

139 We defined two HIV drug resistance outcomes: the level of resistance to DTG and the presence of
140 known drug resistance mutations (DRMs). The Stanford HIV Database version 9.0 and the Stanford
141 HIVdb algorithm²⁷ were used to categorise drug resistance levels as susceptible (score below 10),
142 potential low (10-14), low (15-29), intermediate (30-59) or high (≥ 60). The same approach was used
143 to assess resistance to all other antiretroviral drugs, whereby drug resistance to tenofovir
144 alafenamide (not covered by the Stanford algorithm) was considered equal to tenofovir resistance.
145 Resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) was calculated as the median
146 of the scores for efavirenz, etravirine, nevirapine, and rilpivirine. Resistance to nucleoside reverse
147 transcriptase inhibitors (NRTIs) was calculated as the median of abacavir, zidovudine,
148 emtricitabine/lamivudine, and tenofovir scores (see sensitivity analyses for alternative definitions).

149 **HIV subtyping**

150 We determined HIV subtypes from the integrase gene using COMET (COntext-based Modeling for
151 Expeditious Typing)²⁸ and REGA.²⁹ If REGA and COMET output differed, the subtype with higher
152 support was assigned. As nucleotide sequences were not available for AfA, we used subtype
153 information as provided by the cohort based on reverse transcriptase (RT) and protease. For
154 Aquitaine, information on subtype was used where available, and otherwise considered as unknown.
155 The Aquitaine subtypes were characterised locally using Blast analysis on Smartgene HIV module on
156 two genes at least. In the analysis, we grouped HIV subtypes other than the four most common
157 subtypes (B, C, A, G) as other (subtypes F, AD, AE, D, O6_CPX, 18_CPX, unknown). The appendix (p 1)
158 provides further details.

159

160

161 **Definitions**

162 Individuals who were prescribed raltegravir or elvitegravir before starting the DTG-based regimen
163 were considered exposed to first-generation INSTIs. Viral load testing frequency was calculated for
164 individuals with more than one year of follow-up before the Genotypic Resistance Test (GRT). We
165 quantified HIV viral load as the area under the curve (AUC) of the \log_{10} -transformed viral load
166 measurements from DTG initiation to the GRT sample date. To account for differences in detection
167 limits, we set any viral load measurement below 50 to 0 copies/ml. For individuals who initiated ART
168 with the DTG-based regimen, we excluded high viral loads at ART initiation by setting measurements
169 within the first 180 days from the first HIV RNA measurement to 0. Time on DTG-based ART was
170 calculated in years from DTG initiation to GRT. The ART regimen at GRT was considered the regimen
171 an individual was taking 14 days before the test. If available, GRT results from earlier time points
172 were used to assess prior NRTI resistance.

173 **Statistical analysis**

174 We used descriptive statistics to present the characteristics of the study population and the different
175 INSTI drug-resistance mutations. A negative binomial generalised linear model, adjusting for HIV
176 subtype, exposure to first-generation INSTIs, and sex, was used to analyse the number of major and
177 accessory INSTI drug-resistance mutations. We used ordinal logistic regression to identify risk factors
178 for developing resistance, including cohort as a random effect. We considered variables based on
179 availability and clinical relevance. We included sex, age at initiation and time on the DTG-based
180 regimen, HIV subtype, type of ART (combination ART based on three drugs or more, DTG lamivudine
181 dual therapy, other lamivudine dualtherapy, or monotherapy), exposure to first-generation INSTIs,
182 HIV viral load, viral load testing frequency, and resistance to NRTIs. The missing data was included as
183 a separate category if the sequencing did not cover the RT. All analyses were performed in R, version
184 4.0.5.

185 **Sensitivity analyses**

186 We performed several sensitivity analyses. First, we replaced the NRTI resistance variable with the
187 presence or absence of the M184V/I mutation (sensitivity analysis S1). Further, we performed
188 logistic regression using the same covariables as in the main risk factor analysis, using susceptible
189 versus any DTG resistance as the outcome (S2). We repeated the risk factor analyses excluding study
190 participants where RT was not sequenced (S3). Given the widespread use of tenofovir-lamivudine-
191 dolutegravir (TLD), we restricted the analysis of NRTIs to tenofovir and lamivudine and used the

192 higher resistance level of the two to quantify NRTI resistance (S4). In the subset of people on a DTG +
193 2 NRTI regimen, we calculated NRTI resistance specific to the two NRTIs used in each participant
194 (S5). The main analysis could not assess whether NRTI and NNRTI resistance mutations pre-existed
195 or were acquired on DTG. Sensitivity analysis S6 restricted the study population to participants with
196 available GRTs before experiencing virological failure on the DTG-containing regimen.

197 **Role of the funding source**

198 The funders of the study did not participate in the study design, data collection, data analysis, data
199 interpretation, and writing of the report. The corresponding author had full access to the data of this
200 study and had the final responsibility for the decision to submit for publication.

201 **Results**

202 A total of 750 people met the eligibility criteria and were included in the analysis of mutations
203 conferring resistance to DTG; 677 (90.3%) had more than one year of follow-up since starting the
204 DTG-based regimen and were included in the analysis of risk factors for DTG resistance.

205 **Characteristics of the study population**

206 The study participants included in the two analyses were similar (**Table 1**): most participants were
207 men living with HIV subtype B who were on combination ART with three or more antiretroviral
208 drugs. The median year of starting DTG was 2016. People were on DTG for a median of 16 and 1.7
209 years, and the median AUC of log₁₀ viral load (copies/mL) accumulated during this period was
210 around 3. The first GRT was performed in May 2013, and the last in January 2022. About a third of
211 participants had previously been exposed to first-generation INSTIs. A total of 193 people did not
212 have a CD4 measurement within a year of the GRT, 25 did not have any recorded HIV RNA
213 measurements before the GRT, and in 74 people sequencing did not cover RT. The appendix (p 1)
214 provides further details on the ART regimens.

215 **INSTI mutations and DTG resistance**

216 At least one major or accessory INSTI DRM was found in 100 (13.3%) of the 750 study participants;
217 21 (2.8%) had more than one mutation. Most (713; 95.1%) study participants were fully susceptible
218 to DTG, with potential low, low, intermediate, and high levels of DTG resistance being observed in 8
219 (1.1%), 5 (0.7%), 18 (2.4%) and 6 (0.8%), respectively (**Figure 1**). The INSTI resistance mutations
220 observed in all enrolled people with a DTG resistance score > 0 are shown in the appendix (p 2).

221 The most common major INSTI DRM was R263K (N=11), which only once occurred with another
222 major INSTI DRM (appendix p 2). Other common major mutations included the G140 (N = 10), N155

223 (N = 9), Q148 (N = 8), and the E138 mutation (N = 7). The G118R mutation, which has the strongest
224 impact on susceptibility to DTG, was only observed three times. Among accessory DRMs, E157 (N =
225 25) and T97 (N = 20) were the most common. The distribution of INSTI resistance mutations was
226 similar in people previously exposed to first-generation INSTIs and those not exposed (**Figure 2**).
227 There was no statistically significant association of specific DRMs with first-generation INSTI
228 experience. For HIV subtype, we found a significant association for the accessory INSTI DRM T97 (see
229 appendix p 3). This DRM occurred in 6 of 56 (10.7%) people with HIV subtype A, 4 of 42 (9.5%)
230 people with subtype G, 7 of 444 (1.6%) people with subtype B, and 0 of 71 people with HIV subtype
231 C.

232 The results from the negative binomial model of the number of mutations showed little evidence of
233 a difference between HIV subtypes. The number of INSTI DRMs was higher in first-generation INSTI-
234 exposed people (adjusted RR 1.59, 95% CI 1.03 to 2.48) (**Figure 3**). This association became even
235 stronger when considering the number of major INSTI DRMs (adjusted RR 2.60, 95% CI 1.30 to 5.31)
236 (see appendix p 4 for further details).

237 The prevalence of resistance mutations (low, intermediate or high) to NRTIs and NNRTIs was
238 substantially higher in the presence of DTG resistance (Table 2). Among GRTs with coverage of the
239 RT, the prevalence of at least low level NRTI resistance was 10.1% overall (66 of 654) but 31.8% (7 of
240 22) among those with DTG resistance. The corresponding figures for NNRTI resistance were 12.8%
241 (84 of 654) and 50% (11 of 22).

242 **Risk factors for DTG resistance**

243 The risk of DTG resistance was higher on DTG monotherapy compared to combination ART with >3
244 drugs (adjusted odds ratio [aOR] 37.25, 95% CI 11.17 to 124.2) and for DTG lamivudine dual regimen
245 (aOR 6.59, 95% CI 1.70 to 25.55) (**Figure 4**). The risk of resistance was also increased in the presence
246 of a potential low/low level of NRTI resistance (aOR 4.62, 95% CI 1.24 to 17.2) or intermediate/high
247 level (aOR 7.01, 95% CI 2.52 to 19.48), compared to no NRTI resistance. Non-B HIV subtypes tended
248 towards higher resistance levels, mainly driven by subtype A (aOR 3.27, 95% CI
249 0.90 to 11.87) (appendix p 5). There was a trend for an association of viral load with DTG
250 resistance (aOR 1.42, 95% CI 0.92 to 2.19 per standard deviation of the log₁₀ virus load area under
251 the curve).

252 **Sensitivity analyses**

253 The results of the risk factor analyses were similar when replacing the NRTI resistance variable with
254 the M184V/I mutation (sensitivity analysis S1, appendix p 7) or when analysing susceptible versus

255 any DTG resistance as the outcome in a logistic regression (S2, appendix p 8). The exclusion of 64
256 individuals with missing RT sequences allowed the inclusion of both NRTI and NNRTI resistance in
257 the model. The results for NRTI resistance were similar, and intermediate/high-level NNRTI
258 resistance was also associated with DTG resistance (adjusted OR 4.07, 95% CI 1.07 – 15.5) (S3,
259 appendix p 9). The analysis restricted to lamivudine and tenofovir (S4, appendix p 10) confirmed that
260 DTG resistance was associated with potential low/low and intermediate/high-level resistance to
261 these NRTI drugs. Similarly, when restricting the analysis to people on a DTG regimen with two NRTI
262 backbones, we found similar results for the specific NRTIs (S5, appendix p 11). Finally, in the last
263 sensitivity analysis (S6) we used data on pre-existing NRTI resistance and found that DTG resistance
264 was associated with prior intermediate/high NRTI resistance (appendix p 12).

265 Discussion

266 In this collaborative analysis of eight large cohort studies, we identified INSTI DRMs in 100 of 750
267 (13.3%) PLHIV who experienced virologic failure on DTG-based ART, and resistance to DTG according
268 to the Stanford algorithm was present in 37 (4.9%) individuals. DTG resistance was associated with
269 DTG monotherapy, lamivudine DTG dual therapy, resistance to RT inhibitors, non-B subtype, and HIV
270 viral replication but not with previous first-generation INSTI exposure. A wide range of INSTI DRMs
271 was present. The polymorphic accessory INSTI DRM T97A was detected more frequently in subtypes
272 A and G (compared to subtypes B and C), consistent with previously reported data.³⁰ The major INSTI
273 DRMs at positions 140 and 148 were detected in 5 out of 6 people with high-level DTG resistance, all
274 of whom were first-generation INSTI experienced.

275 DTG monotherapy, DTG lamivudine dual therapy and resistance to the NRTI backbone were most
276 strongly associated with DTG resistance in our study. The complete sequence analysis, which
277 allowed us to distinguish between NRTI and NNRTI resistance, suggests that the association may be
278 mediated via NRTI resistance. It was robust when considering only 3TC and TDF resistance in a
279 sensitivity analysis. As the main analysis was cross-sectional, it did not allow the determination of
280 the timing of NRTI resistance relative to DTG resistance. However, an additional analysis in people
281 with prior resistance tests suggests that NRTI resistance may often have predated DTG resistance.
282 These results indicate that resistance to NRTI backbone drugs from previous regimens may have
283 promoted the emergence of DTG resistance. However, it is also possible that prior NRTI resistance
284 reflects adherence issues, which may facilitate the emergence of DTG resistance.

285 The strong associations of DTG resistance with DTG monotherapy and NRTI resistance are consistent
286 with previous findings,^{10,31,32} but appear to contradict the results from the NADIA trial, which found
287 no evidence that the efficacy of DTG-based ART is affected by resistance to the NRTI backbone.¹⁰

288 However, it should be noted that the NADIA trial examined the risk of virological failure in 235 PLHIV
289 randomised to DTG, resulting in a small number of treatment failures (n=24), while our study
290 focused on the risk of resistance among people who experienced virological failure. Thus, for DTG-
291 based regimens, NRTI resistance may not substantially affect the risk of treatment failure but still
292 increase the risk of resistance in case of failure. Research on other drug classes³³ has shown that
293 drug regimens with high and low genetic barriers can have similar failure rates but different
294 probabilities of acquiring resistance.

295 Our study contributes new information on DTG resistance in PLHIV receiving different DTG-based
296 ART regimens by examining risk factors for DTG resistance in real-world cohort data from different
297 settings. The cohort collaboration resulted in a large dataset of GRT results in people who
298 experienced virological failure on DTG. Our results are central to informing HIV treatment and
299 monitoring policies in the context of the continued expansion of DTG-based treatment regimens.
300 The pooling of data from diverse routine clinical cohorts also has limitations. The data come from
301 individuals receiving any DTG-based regimen in a wide range of different clinical care settings. We
302 only included people who experienced virological failure and had a GRT, but policies and practices
303 regarding when and for whom GRT is done likely differed between cohorts. In our regression
304 models, we accounted for this heterogeneity between cohorts by including cohort as a random
305 effect, but confounding by cohort may still have affected our results. Further, the personalised
306 approach to ART and HIV care in the European settings will not be generalisable to other settings,
307 particularly low- and middle-income countries.

308 A further limitation of our study is the dominance of HIV subtype B, which was expected considering
309 that our study population is comprised mainly of PLHIV from European countries, where subtype B
310 predominates. More data from people with non-B subtypes are needed, and such a study is ongoing
311 within the framework of the International epidemiology Databases to Evaluate AIDS (IeDEA).²⁶ In this
312 study, individuals experiencing failure on DTG-based ART are prospectively enrolled in around forty
313 sites across sub-Saharan Africa, South America, and Asia. Furthermore, the WHO plans to launch
314 sentinel surveys of acquired HIV resistance to DTG among people receiving DTG-based ART.³⁴ We
315 could not assess adherence or drug interactions with rifampicin, which may influence the emergence
316 of DTG resistance.³⁵ Adherence and rifampicin use were not recorded consistently and comparably
317 in the participating cohorts. In our study population, the DTG-based regimens were too
318 heterogeneous to allow investigating DTG resistance outcomes of specific regimens and treatment
319 histories. Lastly, there is growing evidence that mutations outside integrase may confer DTG
320 resistance³⁶⁻³⁸. Our study was based on pol sequences, which did not allow us to investigate these
321 mutations.

322 The associations we found with DTG resistance, resistance to NRTI backbone drugs, HIV-1 subtype,
323 and unsuppressed virus load have important implications for ensuring the long-term sustainability of
324 ART. While INSTI resistance was rare in our population; it is still a concern. Firstly, the duration of
325 DTG therapy and the duration of viraemia whilst receiving DTG was relatively short in our
326 population: the median time on DTG was less than 2 years and drug resistance might emerge more
327 frequently in settings where individuals remain viraemic for a longer time on DTG regimens. This
328 could happen in resource-limited settings where guidelines recommend not switching from DTG-
329 based therapy unless multiple viral loads >1000 copies/mL have been documented and where delays
330 in regimen switching are common.³⁹ Secondly, the strong association of DTG resistance with NRTI
331 resistance suggests that the risk of resistance might be higher in people with previous failure on
332 NNRTI-based first-line therapy, among whom the prevalence of NRTI resistance is much higher than
333 in our study population. The WHO guidelines recommend DTG in 1st-, 2nd- and 3rd-line ART. This
334 multiplicity of roles combined with the recycling of drugs and limited access to viral load and drug
335 resistance testing will facilitate the emergence of DTG resistance. Finally, even a relatively low level
336 of acquired DTG resistance in the millions of people receiving DTG-based ART could lead to rising
337 levels of transmitted INSTI resistance, which could affect both treatment and prevention

338 In conclusion, our study underlines the importance of routine viral load monitoring and resistance
339 testing, especially in treatment-experienced people, to prevent resistance both at the individual
340 patient and the population level and thereby ensure the long-term sustainability of ART.

341 **Figures & tables**

342 **Table 1: Demographics and clinical characteristics in the study population.** People with virological
 343 failure on DTG-based ART with available genotypic resistance tests from eight observational HIV
 344 cohorts were included in the study. Study participants where clinical data was available for at least
 345 one year were considered for analysing risk factors for DTG resistance.


	Analysis of resistance conferring mutations (N=750)	Analysis of risk factors for DTG resistance (N=677)
Sex		
Male	522 (69.6%)	463 (68.4%)
Female	228 (30.4%)	214 (31.6%)
Age at DTG Initiation (years)	46 [38 – 54]	47 [38 – 54]
HIV Subtype		
B	444 (59.2%)	403 (59.5%)
A	56 (7.5%)	53 (7.8%)
C	71 (9.5%)	65 (9.6%)
G	42 (5.6%)	39 (5.8%)
Other*	137 (18.3%)	117 (17.3%)
ART regimen at resistance genotyping		
Combination therapy with ≥3 ARVs	597 (79.6%)	531 (78.4%)
Dual therapy (DTG & Lamivudine)	27(3.6%)	103 (15.2%)
Dual therapy (DTG & other)	107 (14.3%)	25 (3.7%)
Mono therapy	19 (2.5%)	18 (2.7%)
ART duration at DTG initiation (years)	8.7 [2.1 – 17]	9.3 [3.8 – 17]
Missing	7 (0.9%)	7 (1.0%)
Year of DTG initiation	2016 [2015 – 2017]	2016 [2015 – 2017]
Year of genotypic resistance test	2018 [2017 – 2019]	2018 [2017 – 2019]
Availability of additional (prior) GRTs		
Yes	429 (57.2%)	389 (57.5%)
No	321 (42.8%)	288 (42.5%)
Duration on DTG-based ART (years)	1.6 [0.61 – 3.0]	1.7 [0.71 - 3.1]
Exposure to first generation INSTI		
Yes	193 (25.7%)	251 (37.1%)
No	484 (64.5%)	426 (62.9%)
CD4 count at GRT	465 [237 - 718]	483 [250 - 738]
Missing	193 (25.7%)	165 (24.4%)
Viral load AUC (of log₁₀ cp/ml during DTG based ART)		
DTG based ART)	2.9 [1.6 - 4.6]	2.9 [1.7 – 4.6]
Missing	25 (3.3%)	0 (0%)
No. of HIV virus load tests per year	2.7 [2.0 - 4.0]	3.0 [2.0 – 4.0]
Missing	20 (2.7%)	0 (0%)
Cohort		
SHCS	118 (15.7%)	109 (16.1%)
AfA	9 (1.2%)	9 (1.3%)
SAC	92 (12.3%)	87 (12.9%)
Aquitaine	215 (28.7%)	195 (28.8%)
ATHENA	66 (8.8%)	64 (9.5%)

CBC	89 (11.9%)	76 (11.2%)
ICONA	8 (1.1%)	5 (0.7%)
UK CHIC/UKHDRD	153 (20.4%)	132 (19.5%)

346 Numbers (%) and medians [interquartile range] are shown.


347 * Other subtypes are comprised as follows: For the analysis of resistance conferring mutations - Unknown, N=69 (9.2%); F,
348 N=21 (2.8%); AG, N=12 (1.6%); AE, N=11 (1.5%); D, N=11 (1.5%); 06_CPX, N=7 (0.9%); 18_CPX, N=2 (0.3%); 11_CPX, N=1
349 (0.1%); 45_CPX, N=1 (0.1%); AD, N=1 (0.1%); and H, N=1 (0.1%). For the analysis of risk factors for DTG resistance -
350 Unknown, N=60 (8.9%); F, N=16 (2.4%); AG, N=11 (1.6%); D, N=10 (1.5%); AE, N=8 (1.2%); 06_CPX, N=6 (0.9%); 18_CPX,
351 N=2 (0.3%); 11_CPX, N=1 (0.1%); 45_CPX, N=1 (0.1%); AD, N=1 (0.1%); and H, N=1 (0.1%).

352 Abbreviations: ATHENA, the AIDS Therapy Evaluation in the Netherlands cohort; Aquitaine, Agence Nationale de la
353 Recherche sur le SIDA et les hépatites virales (ANRS) CO3 Aquitaine Cohort; ICONA, Italian Cohort of Antiretroviral-Naïve
354 Patients; CBC, Cologne/Bonn Cohort, Germany; SHCS, Swiss HIV Cohort Study; SAC, South Alberta Clinic Cohort, Canada;
355 AfA, Aid for AIDS, South Africa; UK CHIC/UKHDRD, UK Collaborative HIV Cohort (UK CHIC) Study/ UK HIV Drug Resistance
356 Database.




357

358 **Figure 1: Prevalence of DTG resistance and INSTI DRMs.** Genotypic resistance tests of 750 people
 359 with genotypic resistance testing on DTG-based ART were analysed using the Stanford resistance
 360 algorithm to determine INSTI DRMs and resistance level to DTG. Both major and accessory INSTI
 361 DRMs were considered for the number of INSTI DRMs. People with no INSTI DRMs (N = 650, 86.7%),
 362 and who are susceptible to DTG (N = 713, 95.1%) are not displayed.



363

364 Figure 2: INSTI drug resistance mutations found in 750 people experiencing virologic failure on a
 365 DTG-based regimen. Drug resistance mutations were classified as major and accessory according to
 366 the Stanford resistance database²⁷. Bars are coloured by previous history of first generation INSTIs
 367 (raltegravir, elvitegravir).




368

369 **Figure 3: Rate ratio for the number of INSTI DRMs.** A negative binomial generalised linear
 370 model was fit to the number of major and accessory INSTI DRMs in 750 people with
 371 virological failure on DTG-based ART. The plot shows uni- and multivariable point estimates
 372 and 95% confidence intervals of rate ratios.

373 **Table 2: Resistance levels to DTG, non-nucleoside reverse transcriptase inhibitors and nucleotide**
 374 **reverse transcriptase inhibitors.** The number and percentage of people with corresponding drug
 375 resistance levels are given for the entire study population. NRTI resistance level is based on median
 376 resistance score to ABC, AZT, XTC and TDF/TAF. NNRTI resistance level is based on median resistance
 377 score to EFV, ETR, NVP, and RPV.

	DTG resistance level	
	Susceptible & Potential Low (N=721)	Low, Intermediate, High (N=29)
NRTI resistance level		
Susceptible	574 (79.6%)	13 (44.8%)
Potential Low	14 (1.9%)	2 (6.9%)
Low	14 (1.9%)	1 (3.4%)
Intermediate	13 (1.8%)	2 (6.9%)
High	39 (5.4%)	4 (13.8%)
RT not covered in GRT	67 (9.3%)	7 (24.1%)
NNRTI resistance level		
Susceptible	543 (75.3%)	11 (37.9%)
Potential Low	27 (3.7%)	0 (0%)
Low	21 (2.9%)	0 (0%)
Intermediate	39 (5.4%)	4 (13.8%)
High	24 (3.3%)	7 (24.1%)
RT not covered in GRT	67 (9.3%)	7 (24.1%)

378



379

380 **Figure 4: Odds ratios for DTG resistance levels with 95% confidence intervals from uni- and**
 381 **multivariable ordinal logistic models for genotypic DTG resistance.** Cohorts were included as
 382 random effect. DTG resistance levels in people with virological failure on DTG-based ART were
 383 assessed using the Stanford resistance algorithm.

384 **Authors' contributions**

385 Conceptualisation (HFG, JACS, RL, ME, RK), Data curation (TL, SH, SI, HO), Methodology (TL, CS, RK
386 ME, JACS), Formal analysis & Validation (TL, RK), Investigation (TL, SH, SI), Project administration (SH,
387 SI), Resources (HO, KK, JM, AvS, MS, AAM, JG, CS, GM), Software (TL, KK), Supervision (HFG, JACS, RL,
388 ME, RK), Visualisation (TL), Writing – original draft (TL, RL, ME, RK), Writing – review & editing (All
389 authors).

390 TL and RK have directly accessed and verified the underlying data reported in the manuscript. RL, ME
391 and RK contributed equally.

392 **Declaration of interests**

393 SMI reports grant funding from NIH NIAAA for the work of ART-CC (payment to institution). AvS
394 reports funding from the Dutch Ministry of Health, Welfare and Sport for the maintenance of the
395 ATHENA database, and grant funding from the European Centre for Disease Prevention and Control
396 (ECDC) (payment to institution). MJG reports honoraria as Ad Hoc member of HIV National Advisory
397 Board from Merck, Gilead Sciences, and ViiV, and a leadership position as Medical Director S Alberta
398 HIV clinic. CAS has received funding from Gilead Sciences, ViiV Healthcare and Janssen-Cilag for
399 membership of Data Safety and Monitoring Committees, Advisory Committees and for preparation
400 of educational material. HFG has received personal fees from Merck, Gilead Sciences, ViiV, GSK,
401 Janssen, Johnson and Johnson and Novartis, as an advisor/consultant or for DSMB membership and
402 has received a travel grant from Gilead. JACS reports funding for research in this publication from
403 NIH NIAAA (payment to institution), UK NIHR (payment to institution), and the University of Bern
404 (payment to institution). RL reports support for research in this publication by the National Institute
405 of Allergy & Infectious Diseases of the National Institutes of Health under award number
406 R01AI152772, and support from the National Institute of Allergy & Infectious Diseases of the
407 National Institutes of Health under award number R01AI167699 for a separate project pertaining to
408 HIV treatment strategies. ME reports funding for research in this publication from the Swiss National
409 Science Foundation (32FP30-18949) and the National Institutes of Health (Cooperative Agreement
410 AI069924 and R01 AI152772-01). RK reports funding for research in this publication from the Swiss
411 National Science Foundation and the National Institute of Allergy & Infectious Diseases of the
412 National Institutes of Health, and reports grant funding from Gilead Sciences. All other authors
413 declare no competing interest.

414 **Acknowledgements**

415 We would like to acknowledge Anthony Hauser, Suraj Balakrishna, and Marius Zeeb for helpful
416 discussions on data analysis. This study was supported by the National Institute Of Allergy And
417 Infectious Diseases of the National Institutes of Health under Award Number R01AI152772 and the
418 Swiss National Science Foundation (32FP30_207285, 324730_207957). The participating cohorts or
419 cohort collaborations were funded by the Swiss National Science Foundation (33CS30_201369) and
420 the Yvonne Jacob Foundation (for the SHCS), the UK Medical Research Council (grant numbers
421 G0000199, G0600337, G0900274, and M004236/1; for the UK Collaborative HIV Cohort), the
422 National Agency for AIDS Research (France REcherche Nord&Sud Sida-hiv Hépatites), the French
423 Agency for Research on AIDS and Viral Hepatitis –Emerging Infectious Diseases (ANRS–MIE) and the
424 CHU de Bordeaux (for the ANRS CO3 Aquitaine-AquiVIH-NA cohort), the Dutch Ministry of Health
425 (for the ATHENA cohort), the German Center for Infection Research (8018704707) (for the CBC),
426 ICONA Foundation is supported by unrestricted grants from BMS, Gilead Sciences, Janssen, MSD and
427 ViiV Healthcare. AFA is supported via leDEA-SA by the U.S. National Institutes of Health’s National
428 Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child
429 Health and Human Development, Division of Cancer Epidemiology and Genetics, National Cancer
430 Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National
431 Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the
432 National Institute of Diabetes and Digestive and Kidney Diseases and the Fogarty International
433 Center under Award Number U01AI069924. The ART-CC is funded by the US National Institute on
434 Alcohol Abuse and Alcoholism (U01-AA026209). The content is solely the responsibility of the
435 authors and does not necessarily represent the official views of the National Institutes of Health.

436 **Data sharing statement**

437 Data underlying the figures and tables reported in this article may be shared following publication of
438 this article. Researchers may submit a methodologically sound proposal for the use of these data to
439 the corresponding author. De-identified data of individual study participants cannot be made
440 available as they are subject to the respective observational HIV cohorts.

441 **References**

- 442 1. WHO. Update of recommendations on first- and second-line antiretroviral regimens. Geneva,
443 Switzerland:World Health Organization; WHO. 2019. p. 3.
- 444 2. The Lancet HIV. End resistance to dolutegravir roll-out. *Lancet HIV*. 2020 Sep 1;7(9):e593.
- 445 3. Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Genetic barrier to
446 resistance for dolutegravir. *AIDS Rev*. 2015;17(1):56–64.
- 447 4. Cottrell ML, Hadzic T, Kashuba ADM. Clinical pharmacokinetic, pharmacodynamic and drug-
448 interaction profile of the integrase inhibitor dolutegravir. *Clin Pharmacokinet*.

- 449 2013;52(11):981–94.
- 450 5. Cevik M, Orkin C, Sax PE. Emergent resistance to dolutegravir among instinaive patients on
451 first-line or second-line antiretroviral therapy: A review of published cases. *Open Forum*
452 *Infect Dis.* 2020;7(6).
- 453 6. Pena MJ, Chueca N, D’Avolio A, Zarzalejos JM, Garcia F. Virological failure in HIV to triple
454 therapy with dolutegravir-based firstline treatment: Rare but possible. *Open Forum Infect*
455 *Dis.* 2019;6(1).
- 456 7. Scherrer AU, Yang W-L, Kouyos RD, Böni J, Yerly S, Klimkait T, et al. Successful Prevention of
457 Transmission of Integrase Resistance in the Swiss HIV Cohort Study. *J Infect Dis.*
458 2016;214(3):399–402.
- 459 8. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al.
460 Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults
461 with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study.
462 *Lancet.* 2013;382(9893):700–8.
- 463 9. Lepik KJ, Harrigan PR, Yip B, Wang L, Robbins MA, Zhang WW, et al. Emergent drug resistance
464 with integrase strand transfer inhibitor-based regimens. *AIDS.* 2017;31(10):1425–34.
- 465 10. Paton NI, Musaaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Efficacy and safety
466 of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or
467 tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a
468 prospective, multicentre, open-label, factorial, randomised, no. *Lancet HIV.* 2022;1–13.
- 469 11. Han Y-S, Mesplède T, Wainberg MA. Differences among HIV-1 subtypes in drug resistance
470 against integrase inhibitors. *Infect Genet Evol.* 2016;46:286–91.
- 471 12. Brenner BG, Thomas R, Blanco JL, Ibanescu R-I, Oliveira M, Mesplède T, et al. Development of
472 a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading
473 to cross-resistance to integrase inhibitors. *J Antimicrob Chemother.* 2016;71(7):1948–53.
- 474 13. Arimide DA, Szojka ZI, Zealiyas K, Gebreegziabxier A, Adugna F, Sasinovich S, et al. Pre-
475 Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C
476 Infected Patients in Ethiopia. *Viruses.* 2022;14(4).
- 477 14. Akil B, Blick G, Hagins DP, Ramgopal MN, Richmond GJ, Samuel RM, et al. Dolutegravir versus
478 placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated
479 substitutions: 48-week results from VIKING-4, a randomized study. *Antivir Ther.*
480 2015;20(3):343–8.
- 481 15. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in
482 antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-
483 week results of the phase III VIKING-3 study. *J Infect Dis.* 2014;210(3):354–62.
- 484 16. Inzaule SC, Hamers RL, Doherty M, Shafer RW, Bertagnolio S, Rinke de Wit TF. Curbing the
485 rise of HIV drug resistance in low-income and middle-income countries: the role of
486 dolutegravir-containing regimens. *Lancet Infect Dis.* 2019;19(7):e246–52.
- 487 17. Boender TS, Smit C, Van Sighem A, Bezemer D, Ester CJ, Zaheri S, et al. AIDS Therapy
488 Evaluation in the Netherlands (ATHENA) national observational HIV cohort: Cohort profile.
489 *BMJ Open.* 2018;8(9).
- 490 18. Hessamfar M, Colin C, Bruyand M, Decoin M, Bonnet F, Mercié P, et al. Severe morbidity
491 according to sex in the era of combined antiretroviral therapy: The ANRS CO3 aquitaine

- 492 cohort. *PLoS One*. 2014;9(7).
- 493 19. Lepri AC, Phillips AN, Monforte A d'A., Castelli F, Antinori A, De Luca A, et al. When to start
494 highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the
495 ICONA study. *AIDS*. 2001;15(8):983–90.
- 496 20. Ehren K, Hertenstein C, Kümmerle T, Vehreschild JJ, Fischer J, Gillor D, et al. Causes of death
497 in HIV-infected patients from the Cologne-Bonn cohort. *Infection*. 2014;42(1):135–40.
- 498 21. Babiker A, Dunn D, Easterbrook P, Fisher M, Gilson R, Johnson M, et al. The creation of a large
499 UK-based multicentre cohort of HIV-infected individuals: The UK collaborative HIV cohort (UK
500 CHIC) study. *HIV Med*. 2004;5(2):115–24.
- 501 22. Scherrer AU, Traytel A, Braun DL, Calmy A, Battegay M, Cavassini M, et al. Cohort Profile
502 Update: The Swiss HIV Cohort Study (SHCS). *Int J Epidemiol*. 2022;51(1):33-34J.
- 503 23. Beck PL, Gill MJ, Blahey WB, Sutherland LR. HIV-related non-Hodgkin's lymphoma in Calgary.
504 *Can J Infect Dis*. 1996;7(2):115–20.
- 505 24. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, et al. Pharmacy refill
506 adherence compared with CD4 count changes for monitoring HIV-infected adults on
507 antiretroviral therapy. *PLoS Med*. 2008;5(5):0777–88.
- 508 25. May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, et al. Cohort profile:
509 Antiretroviral therapy cohort collaboration (ART-CC). *Int J Epidemiol*. 2014;43(3):691–702.
- 510 26. Chammartin F, Dao Ostinelli CH, Anastos K, Jaquet A, Brazier E, Brown S, et al. International
511 epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019. *BMJ
512 Open*. 2020;10(5).
- 513 27. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. *Clin
514 Infect Dis*. 2006;42(11):1608–18.
- 515 28. Struck D, Lawyer G, Ternes A-M, Schmit J-C, Bercoff DP. COMET: Adaptive context-based
516 modeling for ultrafast HIV-1 subtype identification. *Nucleic Acids Res*. 2014;42(18).
- 517 29. Pineda-Peña A-C, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, et al. Automated
518 subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance
519 evaluation of the new REGA version 3 and seven other tools. *Infect Genet Evol*. 2013;19:337–
520 48.
- 521 30. Abram ME, Ram RR, Margot NA, Barnes TL, White KL, Callebaut C, et al. Lack of impact of pre-
522 existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and
523 treatment outcome. *PLoS One*. 2017;12(2).
- 524 31. Rolle C-P, Nguyen V, Hinestrosa F, DeJesus E. Virologic outcomes of switching to dolutegravir
525 functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective
526 study of treatment-experienced, patients living with HIV. *AIDS Res Ther*. 2021;18(1).
- 527 32. Naeger LK, Harrington P, Komatsu T, Deming D. Effect of dolutegravir functional
528 monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant
529 patients. *Antivir Ther*. 2016;21(6):481–8.
- 530 33. Von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, et al. Emergence of HIV-1 drug
531 resistance in previously untreated patients initiating combination antiretroviral treatment: A
532 comparison of different regimen types. *Arch Intern Med*. 2007;167(16):1782–90.
- 533 34. WHO. Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving

- 534 dolutegravir- containing antiretroviral therapy. Geneva; 2022.
- 535 35. Naidoo A, Naidoo K, Padayatchi N, Dooley KE. Use of integrase inhibitors in HIV-associated
536 tuberculosis in high-burden settings: implementation challenges and research gaps. *Lancet*
537 *HIV*. 2022;9(2):e130–8.
- 538 36. Malet I, Delelis O, Nguyen T, Leducq V, Abdi B, Morand-Joubert L, et al. Variability of the HIV-
539 1 3' polypurine tract (3'PPT) region and implication in integrase inhibitor resistance. *J*
540 *Antimicrob Chemother*. 2019;74(12):3440–4.
- 541 37. Dekker JG, Klaver B, Berkhout B, Das AT. Mutations in the HIV-1 3-Polypurine Tract Can
542 Confer Dolutegravir Resistance. *Antimicrob Agents Chemother*. 2022;66(1).
- 543 38. Hikichi Y, Groebner JL, Wiengand A, Mellors JW, Kearney MF, Freed EO. Mutations outside
544 integrase lead to high-level resistance to dolutegravir [CROI Abstract 103]. In: *Conference on*
545 *Retroviruses and Opportunistic Infections CROI 2023 Abstract eBook*. 2023.
- 546 39. Haas AD, Keiser O, Balestre E, Brown S, Bissagnene E, Chimbetete C, et al. Monitoring and
547 switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa:
548 Collaborative analysis. *Lancet HIV*. 2015;2(7):e271–8.
- 549